Large holder update, amended
Open the filing on sec.gov
Inhibrx Biosciences, Inc. (INBX)
Nasdaq: INBX · Biological Products, (No Diagnostic Substances) · La Jolla, CA · filing with the SEC since 2024
The companyfiscal 2025, as filed
Revenue$1.3M+550.0%
Net income-$140M-108.3%
Earnings per share$-9.04-108.0%
Operating cash flow-$130M+33.2%
Cash$124M-18.6%
Debt$101M
Shareholders’ equity$8.0M-94.0%
Shares, diluted15.5M+3.4%
Return on equity-1752.2%
The recordfrom its filings
Filings in 202650
Newest filingOct 28 · SCHEDULE 13G/A
Annual reportMar 19, 2026
Quarterly reportAug 13, 2026
Next report due10-Q by Nov 14
Insider sales, 12 months$300,000
Insider buys, 12 months$6.3M
Patents granted11
Filer category<br>Emerging growth company
Trailing twelve months to Jun 2026Net income -$138MCash from operations -$132Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Insider trade report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report, amended
Open the filing on sec.gov
Insider trade report, amended
Open the filing on sec.gov
Insider trade report, amended
Open the filing on sec.gov
Insider trade report, amended
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.